TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 121 resultados LastUpdate Última actualización 11/07/2020 [16:36:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 5 nextPage   por página


METHODS AND DEVICE ARRANGEMENT FOR PHYSICAL ACTIVITY THRESHOLDS REDUCING RISKS OF DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATIONS, DEMENTIA, CANCERS AND MORTALITY IN SEDENTARY SUBJECTS

NºPublicación: EP3676847A1 08/07/2020

Solicitante:

GLEAP HEALTH TECH OY [FI]

CN_111343903_A

Resumen de: WO2019043292A1

High blood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given threshold of 2980 steps in the acceleration range 1.3 - 1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.

traducir

METHODS OF WIRELESS COMMUNICATION IN AN INFUSION PUMP SYSTEM

NºPublicación: US2020213946A1 02/07/2020

Solicitante:

TANDEM DIABETES CARE INC [US]

Resumen de: US2020213946A1

Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other multi-purpose consumer electronic device and/or a dedicated remote controller for the infusion pump. Communications among these devices can be coordinated to increase efficiency and conserve battery power.

traducir

EVALUATION AND VISUALIZATION OF GLYCEMIC DYSFUNCTION

NºPublicación: US2020205742A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020205743_A1

Resumen de: US2020205742A1

An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.

traducir

EVALUATION AND VISUALIZATION OF GLYCEMIC DYSFUNCTION

NºPublicación: US2020205744A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020205743_A1

Resumen de: US2020205744A1

An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.

traducir

Compatibility check for continuous glucose monitoring application

NºPublicación: AU2020203890A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020142804_A1

Resumen de: AU2020203890A1

Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.

traducir

SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS

NºPublicación: WO2020139771A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020205704_A1

Resumen de: WO2020139771A1

Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each of the input data items; determining a decision support recommendation based on the process and the input data and presenting the decision support recommendation to the user on a user interface only if the reliability metric exceeds a threshold.

traducir

EVALUATION AND VISUALIZATION OF GLYCEMIC DYSFUNCTION

NºPublicación: WO2020139699A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020205743_A1

Resumen de: WO2020139699A1

An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.

traducir

NONINVASIVE VITAL SIGNS MEASUREMENT SYSTEM

NºPublicación: WO2020140013A1 02/07/2020

Solicitante:

BIONOUS LLC [US]

Resumen de: WO2020140013A1

Methods and apparatus for noninvasive measurement of vital signs is provided. The apparatus comprises at least one sensor configured to sense biological signals including a photoplethysmogram (PPG), and at least one computer processor programmed to determine a plurality of vital signs based, at least in part, on the sensed biological signals, wherein the plurality of vital signs include at least two of heart rate, blood oxygenation, heart rate variability, blood pressure, blood sugar, cholesterol, pulse rate, pulse pressure, temperature, and respiration rate.

traducir

SUSTAINABLE TYPE 2 DIABETES PREVENTION MODULE

NºPublicación: US2020211708A1 02/07/2020

Solicitante:

GERONIMO BUTTON CHRISTINE TINIO [US]
BUTTON TERRY MICHAEL [US]
VERMA ASHISH [US]

Resumen de: US2020211708A1

A method is disclosed for monitoring or delaying or preventing or combinations thereof, the onset of Type 2 diabetes or reducing blood sugar level to a normal range that includes interfacing, via a computer-based system, a user device with a processor in communication with one or more data bases; inputting at least one user profile into one or more of the data bases; inputting data into one or more data bases wherein the data relates to diabetes optimized dietetic or diabetes optimized exercise or weight or combinations for at least one user corresponding to the at least one user profile; and presenting to at least one user a summary of the data input into the one or more data bases wherein the data relates to diabetes optimized dietetic or diabetes optimized exercise or weight or combinations. A corresponding system and an article of manufacturing are also disclosed.

traducir

SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS

NºPublicación: US2020205704A1 02/07/2020

Solicitante:

DEXCOM INC [US]

Resumen de: US2020205704A1

Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each of the input data items; determining a decision support recommendation based on the process and the input data and presenting the decision support recommendation to the user on a user interface only if the reliability metric exceeds a threshold.

traducir

PATCH PUMP SYSTEMS AND APPARATUS FOR MANAGING DIABETES, AND METHODS THEREOF

NºPublicación: US2020206417A1 02/07/2020

Solicitante:

TRIPLE JUMP ISRAEL LTD [IL]

CN_110753561_A

Resumen de: US2020206417A1

Embodiments of the current disclosure are directed toward systems, devices and methods for diabetes management. In particular, the present disclosure relates to systems, devices and methods for dispensing insulin to a patient using a miniaturized and portable patch pump.

traducir

OCCLUSION RESOLUTION IN MEDICATION DELIVERY DEVICES, SYSTEMS, AND METHODS

NºPublicación: US2020206421A1 02/07/2020

Solicitante:

BIGFOOT BIOMEDICAL INC [US]

US_2017203036_A1

Resumen de: US2020206421A1

Methods, devices, and systems of delivering infusion fluid (e.g., medication such as insulin) can detect, at multiple times during a dispensation period of time, a pressure level of the infusion fluid in an infusion fluid pathway, either directly or indirectly. Based on the detected pressure levels, one or more actual dispensation times that are after an intended dispensation time can be determined. In some cases, methods, devices, and systems provided herein can use variable occlusion alarm thresholds, which can depend on variables such as an age of an infusion set and/or a current analyte level. In some cases, methods, devices, and systems provided herein can automate medication delivery and use the actual dispensation times in a control algorithm determining medication deliveries.

traducir

LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE

NºPublicación: US2020206351A1 02/07/2020

Solicitante:

REAL TIME IMAGING TECH LLC [US]

US_2018193462_A1

Resumen de: US2020206351A1

An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

traducir

EVALUATION AND VISUALIZATION OF GLYCEMIC DYSFUNCTION

NºPublicación: US2020205743A1 02/07/2020

Solicitante:

DEXCOM INC [US]

US_2020205744_A1

Resumen de: US2020205743A1

An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.

traducir

METHODS OF WIRELESS COMMUNICATION IN AN INFUSION PUMP SYSTEM

NºPublicación: US2020206420A1 02/07/2020

Solicitante:

TANDEM DIABETES CARE INC [US]

Resumen de: US2020206420A1

Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other remote consumer electronic device and/or a dedicated remote controller for the infusion pump. In order to ensure reliable communication of data, more than one component in a system can be capable of relaying data to another component.

traducir

CONTINUOUS GLUCOSE MONITORING ON-BODY SENSOR HAVING A VISUAL DISPLAY

NºPublicación: EP3673804A1 01/07/2020

Solicitante:

BECTON DICKINSON CO [US]

US_2020008758_A1

Resumen de: EP3673804A1

An on-body sensor (OBS) (10) having a continuous monitoring (CGM) device is disclosed for use in identifying an analyte, such as glucose in blood or interstitial fluid (ISF), using a biomaterial, such as glucose binding protein (GBP), that is brought into contact with the analyte. The on-body sensor (10) incorporating the CGM device includes a cover (25) which provides protection to the CGM device and includes an integrated output display (27). The output display (27) can visually provide data received from the CGM device, to the user without the need for a separate data receiving device.

traducir

ADJUSTABLE PENETRATION DEPTH SYRINGE

NºPublicación: EP3673938A1 01/07/2020

Solicitante:

BECTON DICKINSON CO [US]

US_2018177956_A1

Resumen de: EP3673938A1

A syringe is provided with an assembly received on the distal end for adjusting the penetration depth. In embodiments, the assembly includes a collar attached to the syringe hub which moves with respect to the needle between axial positions depending on the desired needle penetration depth. The adjustable penetration depth syringe is useful in the context of self-administered drugs such as insulin, where a longer length needle is needed to fill a syringe from a vial, but a shorter penetration depth is preferred for administering a subcutaneous injection.

traducir

CONTINUOUS GLUCOSE MONITORS AND RELATED SENSORS UTILIZING MIXED MODEL AND BAYESIAN CALIBRATION ALGORITHMS

NºPublicación: EP3672479A1 01/07/2020

Solicitante:

DEXCOM INC [US]

AU_2018319524_A1

Resumen de: WO2019038661A1

A method for monitoring blood glucose levels includes receiving a time-varying electrical signal from an analyte sensor during a temporal phase of a monitoring session and selecting a calibration model from a plurality of calibration models. The selected calibration model includes one or more calibration model parameters. The method further includes estimating at least one of the one or more calibration model parameters of the selected calibration model based on at least the time-varying electrical signal during the temporal phase and estimating the blood glucose level of the user based on the selected calibration model and the at least one estimated parameter. An apparatus and non-transitory computer readable medium can carry out similar functionality.

traducir

Glucose Sensor

NºPublicación: KR20200077120A 30/06/2020

Solicitante:

동우화인켐주식회사

Resumen de: KR20200077120A

본 발명은 기판; 상기 기판 상에 형성된 전극부; 상기 전극부 상에 상기 전극부를 덮도록 형성된 전극보호 및 전자수송부; 및 상기 전극보호 및 전자수송부 상에 형성된 글루코스 반응부를 포함하고, 상기 전극보호 및 전자수송부는 전극 보호 재료, 전자 수송체 및 친수성 바인더를 포함하는 글루코스 센서를 제공한다.

traducir

SYSTEM AND METHOD FOR CALCULATING THE SAFETY INDEX OF SACCHARIDE INTAKE BASED ON GLUCOSE LOAD INDEX

NºPublicación: KR20200075694A 26/06/2020

Solicitante:

계명대학교산학협력단

Resumen de: KR20200075694A

본 발명은 혈당부하지수에 기반한 당류 섭취 안전지수 산출 시스템에 관한 것으로서, 보다 구체적으로는 당류 섭취 안전지수 산출 시스템으로서, 식품 정보를 저장하는 데이터베이스; 데이터베이스에 저장된 식품 정보를 이용해, 섭취한 식품의 혈당부하지수를 검색하는 검색부; 및 혈당부하지수와 당류 섭취 안전지수 사이의 관계를 이용해, 상기 검색된 혈당부하지수로부터 당류 섭취 안전지수를 산출하는 지수 산출부를 포함하는 것을 그 구성상의 특징으로 한다. 본 발명은 혈당부하지수에 기반한 당류 섭취 안전지수 산출 방법에 관한 것으로서, 보다 구체적으로는 당류 섭취 안전지수 산출 방법으로서, (1) 식품 정보를 데이터베이스에 저장하는 단계; (2) 상기 데이터베이스에 저장된 식품 정보를 이용해, 섭취한 식품의 혈당부하지수를 검색하는 단계; 및 (3) 혈당부하지수와 당류 섭취 안전지수 사이의 관계를 이용해, 상기 검색된 혈당부하지수로부터 당류 섭취 안전지수를 산출하는 단계를 포함하는 것을 그 구성상의 특징으로 한다. 본 발명에서 제안하고 있는 혈당부하지수에 기반한 당류 섭취 안전지수 산출 시스템 및 방법에 따르면, 혈당부하지수와 당류 섭취 안전지수 사이의 관계를 이용해, 혈당부하지수로부터 당�

traducir

Catheter assembly including monitoring capabilities

NºPublicación: AU2020203686A1 25/06/2020

Solicitante:

BARD INC C R [US]

US_2019374162_A1

Resumen de: AU2020203686A1

A catheter assembly or other elongate tubular device for use in establishing vascular or other access within the body of a patient is disclosed. The catheter assembly is equipped with one or more sensors that enable monitoring of one or more physiological aspects of the patient or physical aspect of the catheter assembly itself when the catheter assembly is disposed within the patient. Such aspects include central venous pressure, body temperature, ECG heart signals, oxygen levels, ultrasound data, glucose, etc. The catheter assembly includes the ability to wirelessly transmit or otherwise forward data relating to the detected physiological parameters to another location, such as a patient electronic medical record, smartphone or other mobile device, nurse station, etc. Catheter assemblies configured to detect the frequency of catheter flushing, flushing quality, etc., are also disclosed. ------------------------------------ ---------

traducir

INTEGRATED INSULIN DELIVERY SYSTEM HAVING SAFETY FEATURES TO PREVENT HYPOGLYCEMIA

NºPublicación: US2020197607A1 25/06/2020

Solicitante:

ABBOTT DIABETES CARE INC [US]

US_2019054237_A1

Resumen de: US2020197607A1

Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.

traducir

INTERMITTENT MONITORING

NºPublicación: US2020196922A1 25/06/2020

Solicitante:

DEXCOM INC [US]

WO_2020131942_A1

Resumen de: US2020196922A1

Various examples are directed to systems and methods for patient monitoring. An example method comprises receiving an estimated glucose concentration level of the patient from a continuous glucose monitoring (CGM) system for a first time period. The method may also include receiving non-glucose information relating to the patient for the first time period and determining a relationship between the estimated glucose concentration level and the non-glucose information. The method may also include receiving non-glucose information relating to the patient for a second time period and determining diabetic information about the patient for the second time period based upon the determined relationship and the non-glucose information. The method may include electronically delivering a notification about the diabetic information.

traducir

INTERMITTENT MONITORING

NºPublicación: US2020196923A1 25/06/2020

Solicitante:

DEXCOM INC [US]

WO_2020131942_A1

Resumen de: US2020196923A1

Various examples are directed to systems and methods for monitoring a patient. For example, patient data of a first type may be monitored with a low-fidelity monitoring technique over a first time period. Patient behavior may be evaluated based on the monitored first type of patient data. Patient data of a second type may be monitored over a second time period with a continuous glucose monitor device. A parameter of the continuous glucose monitor device may be based on the evaluated patient behavior during the monitoring.

traducir

INTERSTITIAL FLUID OSMOTIC PRESSURE MEASURING DEVICE SYSTEM AND METHOD

Nº publicación: US2020196917A1 25/06/2020

Solicitante:

LIFECARE AS [NO]

NO_20170927_A1

Resumen de: US2020196917A1

An interstitial fluid glucose measuring device, system and method, the device including first and second cavities, both configured to be in fluid communication with interstitial fluid outside the cavities, the first and second pressure sensors being configured to sense the pressure in the first and second cavities, respectively. The first cavity includes an active solution and is defined in part by a first glucose porous membrane interfacing on one side of the interior of the first cavity and on the other side configured to interface with the interstitial body fluid. The active solution includes a lectin and a polysaccharide.

traducir

Página1 de 5 nextPage por página

punteroimgVolver